Telitacicept Shows Significant Efficacy in IgA Nephropathy: Phase 3 Interim Analysis

A phase 3 interim analysis demonstrates that telitacicept, a dual BAFF/APRIL inhibitor, significantly reduces proteinuria and preserves kidney function in high-risk IgA nephropathy patients, with an acceptable safety profile. These results may alter current management paradigms.

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.